Disclosed is the use of at least one opioid antagonist or a pharmaceutically acceptable salt thereof and at least one opioid agonist or a pharmaceutically acceptable salt thereof in the manufacture of a dosage form for treating urinary retention (ischuria). Specific examples of an opioid antagonist include naloxone, naltrexone and nalbuphine. Specific examples of an opioid agonist include oxycodone, morphine, hydromorphone and oxymorphone.
